The propensity of RNA viruses to revert attenuating mutations contributes to disease and complicates vaccine development. Despite the presence of virulent revertant viruses in some live-attenuated vaccines, disease from vaccination is rare. This suggests that in mixed viral populations, attenuated viruses may limit the pathogenesis of virulent viruses, thus establishing a virulence threshold. Here we examined virulence thresholds using mixtures of virulent and attenuated viruses in a transgenic mouse model of poliovirus infection. We determined that a 1,000-fold excess of the attenuated Sabin strain of poliovirus was protective against disease induced by the virulent Mahoney strain. Protection was induced locally, and inactivated virus conferred protection. Treatment with a poliovirus receptor-blocking antibody phenocopied the protective effect of inactivated viruses in vitro and in vivo, suggesting that one mechanism controlling virulence thresholds may be competition for a viral receptor. Additionally, the type I interferon response reduces poliovirus pathogenesis; therefore, we examined virulence thresholds in mice lacking the alpha/beta interferon receptor. We found that the attenuated virus was virulent in immunodeficient mice due to the enhanced replication and reversion of attenuating mutations. Therefore, while the type I interferon response limits the virulence of the attenuated strain by reducing replication, protection from disease conferred by the attenuated strain in immunocompetent mice can occur independently of replication. Our results identified mechanisms controlling the virulence of mixed viral populations and indicate that live-attenuated vaccines containing virulent virus may be safe, as long as virulent viruses are present at levels below a critical threshold.
RNA viruses pose a unique challenge for the development of antiviral strategies because they exist as diverse populations due to high error frequencies (21) . These mixed viral populations are due to low-fidelity RNA-dependent RNA polymerases and high replicative yields and have been modeled as quasispecies (15-17, 29, 61) . In addition to generating diversity, the high mutation rates confer rapid evolution, complicating antiviral therapy and vaccine development. The importance of an understanding of RNA virus population dynamics has been demonstrated recently for several medically important RNA viruses. Influenza virus and ebolavirus evade the immune system by rapid evolution, HIV frequently develops mutations that confer drug resistance, and hepatitis C virus evolution has been linked to the development of chronic infection (1, 20, 25, 31, 37, 40, 64) . Therefore, an understanding of the dynamics of diverse RNA virus populations is essential for the control of these pathogens.
Despite a worldwide eradication campaign, poliovirus still infects over a hundred thousand people each year, resulting in outbreaks of paralytic, and occasionally fatal, poliomyelitis (56, 65) . Poliovirus is spread by the fecal-oral route, causing paralysis and/or death in approximately 1% of infected humans due to an invasion of the central nervous system (CNS) (49) . In the early 20th century, the incidence of poliovirus disease continued to escalate until the development of the Salk and Sabin vaccines. Both vaccines were highly effective at dramatically decreasing the incidence of poliomyelitis. The oral live-attenuated Sabin poliovirus vaccine is still used in many countries due to its low cost, oral delivery, and long-term immunity.
Despite the success of the live-attenuated Sabin poliovirus vaccine, a reversion of the attenuating mutations can restore virulence and cause vaccine-associated paralytic poliomyelitis. The Sabin poliovirus vaccine contains a mixture of three types of poliovirus attenuated by repeated serial passage, resulting in viral strains with reduced virulence (57) . Each vaccine strain carries multiple point mutations, conferring temperature sensitivity and reduced neurovirulence. Not all mutations in the vaccine strains are attenuating. For example, although the type 1 Sabin strain contains 57 mutations, only 3 are thought to be major attenuating mutations (5, 24, 28, 39, 41) . The mutations in the vaccine strains can revert to virulence via nucleotide substitutions and/or genetic recombination between different poliovirus strains or other enteroviruses (3, 10, 12, 33) . Intrahost genetic change in vaccine recipients leads to approximately 1 case of vaccine-associated paralytic poliomyelitis per 2.5 million doses (2, 23) . This is a special problem for immunodeficient vaccine recipients, who have long-term viral replication and excretion, thus increasing the chances for the reversion and excretion of virulent virus (7, 66) .
Interestingly, Sabin vaccine strain reversion and recombination events are frequent in healthy vaccinees but alone do not account for the development of disease. For example, up to 80% of viral genomes from healthy vaccinees are recombinant (10) . Additionally, a high percentage of healthy vaccinated infants excrete the type 3 Sabin virus, and nearly all of these isolates had undergone a reversion of the single major attenuating mutation in this virus, yet these infants did not develop disease (22, 44, 45) . Finally, it has been shown that the vaccine itself contains revertant, virulent virus as a fraction of the population. However, this small proportion of virulent viruses was unable to cause disease in monkeys unless the virulent revertants were present at levels above approximately 1% of the total (8) . These examples demonstrate that virulent polioviruses likely exist in most individuals vaccinated with the liveattenuated Sabin vaccine; however, unless virulent viruses are present above a certain proportion of the population, no disease develops. An understanding of this "virulence threshold" is likely to be important for the rational design of many liveattenuated vaccines and will aid in our understanding of viral pathogenesis. The amount of virulent virus required for virulence is partly understood, but the mechanisms controlling the development of disease in the presence of mixed viral populations is unclear. Here we modeled the mixed viral populations characteristic of RNA viruses by inoculating mice with different ratios of attenuated and virulent viruses.
Intracellular dominant interference of defective viral genomes was demonstrated previously (9, 53, 63) ; however, the role of attenuated viruses in limiting disease induced by virulent viruses has not been examined extensively in animal models. Teng et al. demonstrated previously that lymphocytic choriomeningitis virus virulence in mice was reduced if the virus was coinoculated with an avirulent strain in a 10-fold excess (62) . In addition, Sanz-Ramos et al. uncovered hidden virulence determinants in mice infected with foot-and-mouth disease virus (58) .
The goal of this study was to determine whether virulence can be masked in a mixed viral population and to determine the mechanisms controlling virulence by using a transgenic mouse model susceptible to poliovirus (55) . Mice are not susceptible to poliovirus unless they express the human poliovirus receptor (PVR/CD155) (35, 55) . When PVR-transgenic mice are injected intramuscularly in the leg, poliovirus enters neurons of the sciatic nerve and is transported by fast retrograde axonal transport to the spinal cord and brain (47, 48, 54) . Poliovirus replicates to high titers in the central nervous system, and mice succumb to disease within 3 to 12 days (54). Here we used PVR-transgenic mice and determined that a 1,000-fold excess of the attenuated type 1 Sabin strain of poliovirus was protective against disease induced by the virulent type 1 Mahoney strain following intramuscular injection. We determined that protection was induced locally and could be conferred independently of viral replication, possibly through viral receptor competition. Additionally, we demonstrated that the type I interferon (IFN) response also limits disease induced by the attenuated strain by reducing the replication and reversion of attenuating mutations. Our results may explain the rare incidence of vaccine-associated paralytic poliomyelitis despite the presence of virulent virus in the vaccine as well as contribute to our understanding of the dynamics of mixed viral populations.
MATERIALS AND METHODS

Cells and viruses.
HeLa cells were grown in Dulbecco's modified Eagle's medium with 10% calf serum as previously described (52) . The virulent type 1 Mahoney strain of poliovirus and its corresponding type 1 attenuated Sabin strain, containing 57 mutations, were propagated and quantified by a plaque assay with HeLa cells as previously described (36, 52) . In order to maintain the attenuating mutations in the type 1 Sabin strain, any propagation of virus was carried out as previously described, at 32°C (5). Furthermore, we confirmed that our inoculum contained most of the major attenuating mutations via sequencing (see Fig. 8B ). Light-sensitive virus was generated by infecting HeLa cells with type 1 Sabin poliovirus or type 1 Mahoney poliovirus in the presence of 10 g/ml of neutral red dye (Sigma), as previously described (36) . The light-sensitive virus stocks were stored and used in the dark to preserve infectivity for viral replication studies (see below). A portion of this viral stock was used to generate inactivated virus. An aliquot of a predetermined titer was removed from the viral stock in the dark, and the aliquot was then exposed to a fluorescent light bulb for 30 min (with vortexing every 5 min) to inactivate the virus (34, 42) . The ratio of culturable light-insensitive PFU to light-sensitive PFU in the inactivated neutral redpoliovirus stock was 1 to 1 ϫ 10 7 . Strain T3SAϩ of reovirus was a generous gift from Terence Dermody (Vanderbilt University) and was generated as previously described (4) .
Mouse infections. This study was carried out in strict accordance with the recommendations in the Guide for the Care and Use of Laboratory Animals (45a). The protocol was approved by the University of Texas (UT) Southwestern Medical Center IACUC (Assurance of Compliance number A3472-01). All efforts were made to minimize suffering. Survival experiments were conducted by using C57BL/6 mice expressing the human poliovirus receptor (PVR/CD155) and C57BL/6 PVR mice deficient for the alpha/beta interferon receptor (PVR-IFNAR Ϫ/Ϫ mice). Both strains were a generous gift from Satoshi Koike (Tokyo, Japan) (35) . Mice were injected with 50 ml poliovirus or reovirus in phosphatebuffered saline (PBS) into the lower part of the hind leg. For all survival studies, mice were monitored twice a day at 10-to 14-h intervals and were euthanized once diseased had progressed past the point where mice could recover from poliovirus infection, defined as having both legs paralyzed. Once this stage of disease is reached, mice do not recover and do not survive more than 24 h. In order to minimize the number of mice used in the study, for all survival curves, the mice inoculated with 1 ϫ 10 5 PFU Mahoney virus alone are represented as a combined survival curve containing data for all of the mice used as controls (inoculated with 1 ϫ 10 5 PFU Mahoney virus) compared to the various experimental manipulations throughout the study. Although the data for mice inoculated with 1 ϫ 10 5 PFU Mahoney virus alone are pooled for the figures, several mice were infected with 1 ϫ 10 5 PFU Mahoney virus alone for each relevant experiment to ensure reproducibility. For experiments to increase axonal transport via muscle damage, needle sticks were given by inserting a 28-gauge needle into the leg 4 or 5 times twice daily for 3 days (36) . For data in Fig. 6C , PVR mice were injected with a mixture of 1 ϫ 10 5 PFU Mahoney virus and either 100 g of anti-CD155/PVR IgG1 antibody (Santa Cruz) or 100 g of IgG1 isotype control antibody (BioLegend), and survival was monitored.
Plaque assay and tissue titers. Tissues were harvested from mice at disease onset, as previously described (36) , and processed by a Bullet Blender tissue homogenizer (Next Advanced Inc., Averill Park, NY) according to the manufacturer's instructions, followed by freeze-thawing three times to release virus (36) . The viral yield was determined by titer analysis of tissue supernatants on HeLa cells. The type 1 Sabin strain of poliovirus is temperature sensitive, yielding small plaques at 37°C. Therefore, in order to distinguish between the Sabin and Mahoney poliovirus strains, we used a plaque size assay performed at 37°C for 2 days. We compared the plaque sizes of Sabin virus and Mahoney virus to the plaques obtained from tissue samples to distinguish between the virus strains.
Viral replication assay. Mice were infected intramuscularly with light-sensitive virus, in the dark, using a red safety light. As described above, after infection, tissues were harvested from mice at various time points and processed by a Bullet Blender tissue homogenizer (Next Advanced Inc., Averill Park, NY), followed by freeze-thawing three times to release virus. All processing and freeze-thaw steps were carried out in the dark (36). The tissue supernatant was then collected, and each sample was split in half: one half of the sample was kept in the dark, and the other half of the sample was exposed to a fluorescent light bulb for 30 min to inactivate any virus that had not replicated. The titers of the "light" and "dark" aliquots from each sample were then determined on HeLa cells, and titers were compared to determine the percentages of virus in each muscle sample that had undergone replication. The replication percentage was calculated by dividing the titer from the light aliquot by the titer from the dark aliquot and multiplying the value by 100.
In vitro infection assays. A total of 1 ϫ 10 6 HeLa cells were infected with 1 ϫ Viral replication in the presence of interferon. A total of 1 ϫ 10 6 HeLa cells were pretreated with 100 units/ml of IFN-2␣ (a gift from Michael Gale, University of Washington) for 48 h and then infected with 1 ϫ 10 7 PFU Sabin or Mahoney poliovirus (MOI of 10) for 6 h, and the subsequent cell-associated viral yield was determined by plaque assay and compared to that of cells infected in the absence of interferon (14) .
Sequencing of the 5 noncoding region. Viral RNA was purified from tissue homogenates from mice that had succumbed to disease after infection, via TRIzol extraction (Invitrogen, Carlsbad, CA). Reverse transcription was performed with SuperScript II reverse transcriptase (RT) (Invitrogen), using an antisense primer in the capsid coding region (5Ј-CGAAGCCGCGTTACTAG C-3Ј). The 5Ј noncoding region was then amplified by using PCR with primers 5Ј-GGTGGTGTAATTAATGGTAG-3Ј and 5Ј-TTAAAACAGCTCTGGGGT TG-3Ј. PCR products were sequenced by the UT Southwestern McDermott Sequencing Center by use of an antisense primer (5Ј-AAAGTCGACTCCAGC AAACAGATAGGGCC-3Ј).
RESULTS
Virulence can be masked in mixed viral populations. In order to study potential virulence thresholds, we created a mixed pool of viruses to mimic a viral population containing an attenuated viral strain (type 1 Sabin poliovirus) in excess of its parental virulent strain (type 1 Mahoney poliovirus). The intramuscular injection of up to 1 ϫ 10 8 PFU of attenuated Sabin 1 poliovirus did not induce disease in PVR mice. When 1 ϫ 10 5 PFU of virulent Mahoney poliovirus was inoculated alone intramuscularly into PVR mice, 76% of the mice succumbed to disease (Fig. 1A , black line). However, when PVR mice were inoculated intramuscularly with the mixed population of 1 ϫ 10 5 PFU of Mahoney poliovirus and 1 ϫ 10 7 PFU of Sabin poliovirus, only 57% of mice succumbed to disease (Fig. 1A , dashed gray line). These results suggest that a 100-fold excess of the attenuated virus conferred mild protection against disease induced by virulent virus and delayed the onset of disease; therefore, we increased the amount of attenuated virus to a 1,000-fold excess. When PVR mice were inoculated intramuscularly with 1 ϫ 10 5 PFU Mahoney poliovirus and 1 ϫ 10 8 PFU Sabin poliovirus, we found significant protection, with only 25% of mice succumbing to disease (P Ͻ 0.05 by log rank test) (Fig. 1A , light gray line). The 75% survival rate was impressive considering that mice in this group received the same amount of virulent virus as the group receiving the virulent Mahoney virus inoculum alone, where only 24% of mice survived. These results suggest that the attenuated Sabin strain was able to mask the virulence of the Mahoney strain, provided that the attenuated strain was present in a 1,000-fold excess. To test whether the observed virulence threshold exists with smaller amounts of virus comparable to the live-attenuated vaccine dose of ϳ1 ϫ 10 5 PFU, we examined Sabin virusmediated protection in hypersusceptible young mice (26) . When we inoculated 3-week-old PVR mice intramuscularly with 1 ϫ 10 3 PFU Mahoney virus, 63% of mice succumbed to disease. However, when a 1,000-fold excess of attenuated virus (1 ϫ 10 6 PFU Sabin virus) was coinoculated, only 17% of mice succumbed to disease (Fig. 1B , dashed gray line), suggesting that the 1,000:1 ratio holds true even when less virus is inoculated. Taken together, these results demonstrate that virulence can be masked in mixed viral populations when attenuated virus is present in a 1,000-fold excess over the virulent virus.
Masking of virulence is induced at the site of inoculation. To mechanistically dissect how attenuated viruses protect against virulent virus-induced disease, we first determined whether the effect was induced systemically or locally. PVR mice were inoculated with 1 ϫ 10 5 PFU Mahoney virus in the left hind limb and 1 ϫ 10 8 PFU Sabin virus in the right hind limb, and mice were observed for disease. If the protective effect conferred by attenuated viruses occurs through a systemic response, such as humoral immunity, then protection in these mice should be maintained, since the same total amount of virus was inoculated. However, if the protective effect occurs Mice were euthanized after both legs were paralyzed. Only 6 to 8 of the 3-week-old mice were used per group; therefore, despite the absence of a statistically significant difference between groups, the survival curve of the 3-week-old mice had the same trend as that of the adult mice.
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locally, requiring both strains of virus at the same site, then the previously observed protective effect would be lost. In mice inoculated with 1 ϫ 10 5 PFU Mahoney virus in the left hind limb and 1 ϫ 10 8 PFU Sabin virus in the right hind limb, the mortality was equivalent to that of mice inoculated with Mahoney virus alone (Fig. 2) , indicating that the protective effect was lost. These results suggest that virulence thresholds in this system were induced locally and not through a systemic response.
Reducing viral transport barriers does not affect protection by attenuated viruses. Since the protection conferred by attenuated viruses occurred locally, and we previously found that the local inefficient retrograde axonal transport of poliovirus in neurons limits pathogenesis in mice (36), we tested whether excess attenuated virus exacerbates the retrograde axonal transport inefficiency, thereby establishing protection. Previously, in a mouse model of poliovirus infection in the nervous system, we demonstrated that a major barrier to viral dissemination is inefficient retrograde axonal transport (36) . We showed that needle-stick-mediated muscle damage increased the retrograde axonal transport efficiency of poliovirus and a nonviral protein in the sciatic nerve. Furthermore, we found that increasing the transport efficiency of poliovirus via muscle damage increased the diversity of the viral population that reached the brain and increased viral pathogenesis to the same extent that a deficient type I interferon response contributed to disease (36) . Therefore, since this local transport barrier has a substantial effect on pathogenesis in the mouse model, we wanted to examine whether it influences virulence thresholds of mixed viral populations. In order to determine whether an increase of the retrograde axonal transport efficiency impacts virulence thresholds, we injected PVR mice intramuscularly with 1 ϫ 10 5 PFU Mahoney virus, 1 ϫ 10 8 PFU Sabin virus, or both viral strains, and a subset of each of these groups was given needle-stick-mediated muscle damage (27, 36) . When mice inoculated with 1 ϫ 10 5 PFU Mahoney virus were given needle sticks to increase transport efficiency, 100% of mice succumbed to disease by day 10 postinfection (Fig. 3, black dashed line). However, needle-stick-mediated muscle damage had no effect on pathogenesis in mice inoculated with both viruses (Fig. 3 , light gray line and dashed gray line). Therefore, although the inefficient retrograde axonal transport barrier contributes to local protection against viral spread to the central nervous system, it does not appear to contribute to the protective effect conferred by excess attenuated viruses in mice.
Protection can be conferred by a replication-independent mechanism. Theoretically, attenuated viruses could protect against disease induced by virulent viruses through replicationdependent or replication-independent mechanisms; therefore, we evaluated whether the protection against virulence in mixed populations was dependent on replication by using replicationincompetent inactivated viruses. Poliovirus propagated in the presence of neutral red dye is light sensitive, and the exposure of the stock to light inactivates the virus, generating intact but replication-incompetent viruses (34) . PVR mice were inoculated intramuscularly with 1 ϫ 10 5 PFU Mahoney virus, 1 ϫ 10 8 PFU inactivated Sabin virus, or both. Only 27% of mice succumbed to disease in the groups receiving the Mahoney and inactivated Sabin viruses, comparable to the 25% mortality observed with replication-competent Sabin virus, indicating that protection can be conferred by a replication-independent mechanism (Fig. 4A) . Since the attenuated Sabin poliovirus strain is antigenically different from the Mahoney poliovirus strain, we evaluated whether inactivated Mahoney poliovirus could protect against replication-competent Mahoney poliovirus disease. PVR mice were inoculated intramuscularly with 1 ϫ 10 5 PFU Mahoney virus, 1 ϫ 10 8 PFU inactivated Mahoney virus, or both. Only 13% of mice succumbed to disease in the group receiving inactivated Mahoney virus and replication-competent Mahoney virus (Fig. 4B) , comparable to the 25% mortality observed for the group that received repli- 
cation-competent Sabin virus (Fig. 1A) . Taken together, these data suggest that protection against virulence can be conferred by a replication-independent mechanism. Protection is not conferred by a heterologous virus, reovirus. After determining that the mechanism of protection is due to a local, replication-independent mechanism, we next sought to determine whether the effect was due to the attenuated virions or a local immune response from the abundance of exogenous antigen. To distinguish between these two possibilities, we infected mice with type 1 Mahoney poliovirus in the presence of a heterologous virus, reovirus strain T3SAϩ (4), which does not cause disease in intramuscularly injected adult mice. If excess reovirus protected against Mahoney poliovirusinduced disease, this would suggest that a local immune response might be mediating protection. However, if excess reovirus did not protect against Mahoney poliovirus-induced disease, this would suggest that a virus-specific mechanism was mediating protection. Therefore, we infected mice with 1 ϫ 10 8 PFU of reovirus alone, 1 ϫ 10 8 PFU of reovirus and 1 ϫ 10 5 PFU of Mahoney poliovirus, or 1 ϫ 10 5 PFU of Mahoney poliovirus alone and monitored disease. We found that mice infected with reovirus alone showed no signs of disease, whereas mice infected with Mahoney poliovirus alone or Mahoney poliovirus with reovirus had equivalent levels of disease (24% and 25% survival, respectively) (Fig. 5) .
Protection can be conferred by blocking the viral receptor. Since attenuated poliovirus can mask virulence in a virus-specific, replication-independent manner, we considered whether competition for a limited resource, such as the viral receptor PVR, contributes to the protective effect. We began by examining whether inactivated Sabin virus could reduce the yield of Mahoney virus in cell culture infections. We infected PVRexpressing HeLa cells with 1 ϫ 10 7 PFU Mahoney virus (MOI of 10) in the presence or absence of inactivated Sabin virus at 1:0, 1:1, 1:3, 1:10, 1:30 1:100, 1:300, and 1:1,000 ratios; harvested cell-associated virus at 5 h postinfection; and quantified the viral yield by a plaque assay (Fig. 6A) . We found that a 100-fold excess of inactivated Sabin virus significantly reduced virulent Mahoney virus yields in HeLa cells (P Ͻ 0.001 by Student's t test), suggesting that excess replication-incompetent virus limits the replication of virulent virus in vitro.
To examine whether PVR availability influences virulence thresholds, we assessed the effect of treatment with an anti-PVR antibody on viral replication and pathogenesis. First, we incubated cells with increasing concentrations of anti-PVR antibody, infected cells with 1 ϫ 10 5 PFU Mahoney poliovirus (MOI of 10), and quantified the viral yields. HeLa cells were preincubated with 0.1, 1, 10, or 100 g of either an anti-CD155/ PVR antibody or an anti-IgG1 isotype control antibody, washed, and then infected with virulent virus. After 10 min, nonbound virus was removed by washing, and after 5 h, the amount of cell-associated virus was quantified. Viral yields in the presence of the anti-PVR antibody were comparable to those obtained with excess inactivated virus, with an inverse correlation between the amount of anti-PVR antibody and the viral yield (P Ͻ 0.001 by Student's t test) (Fig. 6B, black line) . Because the PVR blockade phenocopied the yield reduction conferred by inactivated viruses in vitro, we examined whether anti-PVR antibody treatment would also limit Mahoney polio- virus pathogenesis in vivo. When PVR mice were inoculated intramuscularly with a mixture of 1 ϫ 10 5 PFU Mahoney poliovirus and 100 g of the anti-IgG1 isotype control antibody, 86% of mice succumbed to disease. However, when PVR mice were inoculated intramuscularly with a mixture of 1 ϫ 10 5 PFU Mahoney poliovirus and 100 g of the anti-CD155/PVR antibody, we found significant protection, with only 38% of mice succumbing to disease (P Ͻ 0.05 by log rank test) (Fig.  6C, black line) . Therefore, both our in vitro and in vivo data indicate that reduced virulence and pathogenesis in mixed viral populations can be conferred by competition for PVR. Taken together, these results indicate that one mechanism of protection establishing the virulence threshold, conferred by attenuated and inactivated viruses, may occur through local PVR competition.
The type I interferon response contributes to protection. Although inactivated virus was sufficient to induce protection from virulent virus-induced disease, we wondered whether any additional host barriers, such as the innate immune response, could contribute to protection conferred by attenuated viruses. By demonstrating that the protective effect required that the virus be inoculated at the same site, we excluded systemic adaptive immunity as a major mechanism controlling virulence thresholds in this system. Previously, the type I interferon response was shown to control poliovirus pathogenesis (30) ; therefore, we examined whether the type I interferon response impacts virulence thresholds. We used PVR-transgenic mice lacking the alpha/beta interferon receptor (PVR-IFNAR Ϫ/Ϫ mice) to determine the role of interferon in controlling virulence (46) . PVR-IFNAR Ϫ/Ϫ mice were inoculated intramuscularly with 1 ϫ 10 5 PFU Mahoney virus, 1 ϫ 10 8 PFU Sabin virus, or both. Unlike in our previous experiments with immunocompetent mice, 100% of the mice in all groups succumbed to disease (Fig. 7A) . To determine which viruses reached the brain, thereby contributing to disease, we initially used a plaque phenotype titer assay to differentiate between the Mahoney and Sabin viruses based on plaque size. The attenuated Sabin strain is temperature sensitive and has a small-plaque phenotype at 37°C, so we used this feature to distinguish between the Sabin and Mahoney strains. Tissue-derived viruses were examined by plaque assay along with cell culture-derived Mahoney or Sabin viruses as controls to facilitate a comparison of plaque sizes. In muscle there was a combination of small and large plaques, suggesting the presence of the Sabin and Mahoney viruses, respectively. However, in the brain, only small plaques, characteristic of the Sabin strain, were present (Fig.  7B ). This suggested that in mice with a deficient type I interferon response, the Sabin strain may have contributed to the onset of disease.
To determine whether the lack of a type I interferon response facilitated viral replication and Sabin virus virulence, several additional experiments were performed. First, we quantified viral titers in the tissues along the viral trafficking route to the brain and, not surprisingly, found higher viral titers in all tissues of PVR-IFNAR Ϫ/Ϫ mice than in PVR mice (P Ͻ 0.01 by one-way analysis of variance [ANOVA]) (Fig. 7C,  black inverted triangles) . The interferon response limited viral replication primarily in the periphery since there was a 36-fold difference in virus muscle titers and a negligible difference in brain titers. This finding suggested that in the absence of an efficient type I interferon response, even the Sabin strain of poliovirus was able to replicate efficiently in vivo. Next, we quantified viral replication in vitro in the presence or absence of IFN-2␣ treatment. Cells were pretreated with or without IFN-2␣ for 48 h and infected with 1 ϫ 10 7 PFU of Sabin or Mahoney viruses, each at an MOI of 10, and cell-associated virus was harvested at 6 h postinfection and quantified by plaque assay. Sabin virus titers were 44-fold higher in the absence of interferon, suggesting that the attenuated Sabin strain is highly sensitive to interferon but is able to efficiently replicate in the absence of a type I interferon response (Fig.  7D) . Furthermore, Mahoney virus titers were only 17-fold higher in the absence of interferon, suggesting that interferon treatment exerts more of an effect on Sabin virus replication than on Mahoney virus replication (Fig. 7D) .
The enhanced replication of the Sabin strain in the absence of type I interferon (Fig. 7C and D) , and the plaque phenotype suggesting that the Sabin strain was present in brain (Fig. 7B) , led us to hypothesize that the attenuating mutations in the Sabin strain reverted in PVR-IFNAR Ϫ/Ϫ mice and that the revertant viruses induced disease. Therefore, we performed a sequence analysis of the 5Ј noncoding region to determine whether the major attenuating mutations responsible for protection from neurovirulence had reverted. Sequence analysis revealed that the Sabin strain was present in the brains of PVR-IFNAR Ϫ/Ϫ mice and that the major attenuating mutation G480A had reverted (Fig. 8A) . In addition, we found a mutation at position 189, which frequently accompanies the G480A reversion and contributes to decreased temperature sensitivity and increased neurovirulence (5, 24, 28, 32, 41, 43 , 67). The sequence at position C355, reported as U in the published type I Sabin strain sequence, matched our inoculum strain, as did two additional sites at positions 649 and 674, confirming that the brain virus was the reverted Sabin strain rather than the Mahoney strain. Our data suggest that Sabin poliovirus replicates efficiently in PVR-IFNAR Ϫ/Ϫ mice, facilitating the reversion of major attenuating mutations and the development of disease; however, the replication efficiency of Sabin poliovirus in immunocompetent PVR mice, which survive infection, is unknown. Is Sabin poliovirus replication so minimal in PVR mice that a reversion of attenuating mutations is a rare event, thereby facilitating the establishment of protection from Mahoney poliovirus-induced disease? Koike et al. demonstrated previously that Sabin poliovirus has diminished replication in the CNS compared to that of Mahoney poliovirus (35) . In our study the virulence threshold was established in muscle, so we determined whether Sabin poliovirus has limited replication in muscle of immunocompetent PVR mice. We quantified viral replication kinetics in vivo using light-sensitive viruses, as previously described (36) . Poliovirus propagated in the presence of neutral red dye is light sensitive due to dye-mediated RNA inactivation; however, upon replication the dye is absent in progeny virions, making them light insensitive. By quantifying the ratio of light-sensitive to light-insensitive viruses, replication can be quantified. PVR mice were inoculated intramuscularly with 2 ϫ 10 7 PFU of light-sensitive Sabin poliovirus in the dark, and muscle was harvested at 6 hpi and 30 hpi and processed to determine the percentage of viral replication (see Materials and Methods). We found that for the Sabin poliovirus strain, only 6.3% of the virus in muscle had undergone replication at 6 hpi and 28% had undergone replication at 30 hpi (Fig. 8B) . These replication kinetics are much slower than what we and others (11) have previously observed for the Mahoney strain. Specifically, we previously found that 25% of the Mahoney virus in muscle had undergone replication at 6 hpi and that 60% had undergone replication at 30 hpi (36) . The delayed replication kinetics for the Sabin strain suggest that it has reduced replication in vitro and in vivo in the presence of an intact interferon response.
Taken together, these data suggest that Sabin virus replicates more efficiently in the periphery in the absence of a type I interferon response and reverts major attenuating mutations culminating in disease. In immunocompetent mice, Sabin poliovirus replication is diminished. Therefore, the type I interferon response appears to play a major role in limiting the pathogenesis of the attenuated Sabin strain by limiting replication and the potential for reversion.
DISCUSSION
An understanding of the dynamics of diverse and highly evolvable RNA virus populations within animal hosts is essential to an understanding of the pathogenesis of RNA viruses. These highly error-prone viruses are thought to have evolved the perfect mutation rate, where too few mutations limit the ability of the virus to adapt and cope with selective pressure, while too many mutations can lead to error catastrophe and defective genomes. The resultant quasispecies creates a dynamic population capable of altered host and cell tropism, immune evasion, drug escape, and recombination (38) . It was shown previously that the dynamics of an RNA virus quasispecies can be impacted by the host as well as other viruses in the population (59) . Two well-characterized mechanisms by which the viral population can be influenced by the composition and diversity of the viral quasispecies include complementation and interference, both of which require viral replication (51, 60, 63) . In this work, we focused on the interplay between attenuated and virulent viruses in mixed populations, and we describe a novel replication-independent mechanism that influences viral pathogenesis. Despite the fact that virulent viruses are present in the live-attenuated Sabin poliovirus vaccine, and attenuating mutations frequently revert during replication in vaccinated individuals, vaccine-associated paralytic poliomyelitis is very rare (2) . This suggests that host or viral factors limit the spread of virulent viruses, thereby limiting disease (59) . Through this process, a virulence threshold is established. In this study, we demonstrated that virulence was masked in mixed viral populations when the attenuated strain was at least 1,000-fold in excess of the virulent strain (Fig. 1) . We found that the protection induced by excess attenuated viruses was conferred locally, requiring the virulent and attenuated viruses to be present at the same site within the host (Fig. 2) .
We previously found that inefficient retrograde axonal transport limited poliovirus pathogenesis in a mouse model of viral infection in the nervous system (36), and since this was a local host barrier, we examined whether this contributed to the protection conferred by the attenuated viruses in the mixture. However, an increase of the viral transport efficiency had no effect on the protection conferred by attenuated viruses (Fig.  3) , suggesting an alternative mechanism of protection.
To further delineate the mechanism conferring protection, we determined whether attenuated viruses could protect against disease induced by virulent viruses through replicationdependent or replication-independent mechanisms. Using replication incompetent viruses, we demonstrated that protection was induced independently of viral replication (Fig. 4) . Because inactivated viruses were sufficient for protection and protection was conferred locally, we hypothesized that excess inactivated or attenuated viruses may compete with virulent viruses for an extracellular factor or a replication-independent resource, such as a viral receptor.
We began exploring this hypothesis by first determining whether protection was a virus-specific effect. If the mechanism modulating the virulence threshold involved competition for a specific cellular resource, such as a viral receptor, this would require coinoculation with a virus that uses the same receptor. Therefore, we evaluated whether reovirus, which does not use CD155/PVR for entry, confers protection against Mahoney poliovirus. We found that the protective effect was absent in the presence of reovirus, suggesting that protection against poliovirus virulence is virus specific.
Receptors control viral entry, influence cell and host tropism, and are a requirement for virulence. Therefore, we determined whether competition for the poliovirus receptor plays a role in establishing virulence thresholds. We demonstrated that excess inactivated virus reduced the yields of virulent virus in vitro. The viral yield in vitro was similarly reduced in the presence of a PVR-blocking antibody (Fig. 6) . Furthermore, a reduction of the receptor availability in vivo by the infection of mice in the presence of a PVR-blocking antibody reduced pathogenesis. This finding may explain why an increase of the viral transport in neurons had no effect on the virulence threshold (Fig. 3) , despite our previous findings that increasing retrograde axonal transport increases pathogenesis (36) . In this instance the protective effect conferred by the presence of the attenuated strain was induced prior to viral entry into neurons; therefore, an increase of the transport of virus in neurons had little to no effect on protection. Because the viral yield inhibition by inactivated virus was dependent on PVR expression, and the blocking of PVR by antibody treatment phenocopied the inactivated virus inhibition in vitro and in vivo, competition for the viral receptor may play a role in the establishment of virulence thresholds. This finding is novel because previously described mechanisms that modulate virulence within a viral population require viral replication (63) .
While the protective effects of excess attenuated viruses were replication independent, we wanted to determine whether other mechanisms could also contribute to virulence thresholds. The type I interferon response has been shown to play a role in limiting viral pathogenesis; therefore, we also examined whether the interferon response could limit virulence in our system. Using PVR-IFNAR Ϫ/Ϫ mice, we found that a deficient type I interferon response provided an environment where attenuated viruses could replicate efficiently, revert attenuating mutations, and induce disease ( Fig. 7 and 8) . We demonstrated this effect by showing that the virus found in brain was the Sabin strain (small-plaque phenotype shown in Fig. 7B ) that had undergone a reversion of the major attenuating mutation, conferring neurovirulence (Fig. 8A) . Enhanced viral replication in the absence of a type I interferon response likely contributed to this effect, since viral titers were higher in all tissues of PVR-IFNAR Ϫ/Ϫ mice than in tissues of PVR mice (Fig. 7C) , and in in vitro infections with equal amounts of virus, the Sabin strain replicated less efficiently in the presence of interferon (Fig. 7D) . These results mimic the enhanced viral replication and reversion of attenuating mutations in immunocompromised individuals administered the attenuated poliovirus vaccine (7, 67) . In PVR mice with intact immune systems, Sabin poliovirus has reduced replication in the nervous system compared to that of the Mahoney strain (35) . We demonstrated that the same is true for muscle (Fig. 8B) , suggesting that in the presence of a robust interferon response, the replication of the Sabin strain is limited. Perhaps, the Sabin strain is more susceptible to interferon due to reduced replication kinetics. This could explain why, despite an inoculum of 1 ϫ 10 8 PFU of Sabin poliovirus, PVR mice fail to succumb to disease. Therefore, the type I interferon response plays an important role in limiting virulence by reducing viral replication and subsequent reversion.
In this work, we demonstrated that the attenuated Sabin strain of poliovirus was able to protect against the neurovirulent Mahoney strain of poliovirus despite the enhanced replication capacity, temperature stability, and increased neurovirulence of the Mahoney strain (5, 6, 10, 24, 50) . It was shown previously that a diverse quasispecies can protect against viruses with a virulent or adapted phenotype (13, 18, 19) . Our results suggest that attenuated viruses significantly reduce virulent virus-induced disease, as long as the attenuated viruses are present in at least a 1,000-fold excess. Teng et al. demonstrated previously that a 10-fold excess of avirulent lymphocytic choriomeningitis virus was sufficient to limit disease induced by a virulent virus, suggesting that virulence thresholds may vary depending on the virus type (62) . It is important to keep in mind that the particle-to-PFU ratio of poliovirus is greater 9786 LANCASTER AND PFEIFFER J. VIROL.
than 100:1, meaning that only 1 of every 100 particles is infectious (49) . Therefore, poliovirus and many other viruses have evolved in the presence of defective particles, which may modulate virulence through multiple mechanisms. The model of a mixed viral population used in this study, comprised of attenuated and virulent viral strains, could be used for future studies to elucidate additional mechanisms whereby virulence thresholds can be established. It would be interesting to determine if competition for receptors also occurs in the gut or lymphatic tissue after oral vaccination. Overall, these results contribute to our understanding of viral dynamics and may explain the relative safety of the live-attenuated oral Sabin poliovirus vaccine despite the presence of virulent revertant viruses in the host.
